These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22993549)

  • 1. Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients.
    Balogh GA; Mailo D; Nardi H; Corte MM; Vincent E; Barutta E; Lizarraga G; Lizarraga P; Montero H; Gentili R
    Exp Ther Med; 2010 Mar; 1(2):357-361. PubMed ID: 22993549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer.
    Balogh GA; Mailo DA; Corte MM; Roncoroni P; Nardi H; Vincent E; Martinez D; Cafasso ME; Frizza A; Ponce G; Vincent E; Barutta E; Lizarraga P; Lizarraga G; Monti C; Paolillo E; Vincent R; Quatroquio R; Grimi C; Maturi H; Aimale M; Spinsanti C; Montero H; Santiago J; Shulman L; Rivadulla M; Machiavelli M; Salum G; Cuevas MA; Picolini J; Gentili A; Gentili R; Mordoh J
    Int J Oncol; 2006 Apr; 28(4):995-1002. PubMed ID: 16525651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
    Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
    Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
    Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
    Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 and Twist1 Co-Expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer.
    Zhang YQ; Zhang F; Zeng YZ; Chen M; Huang WH; Wu JD; Chen WL; Gao WL; Bai JW; Yang RQ; Zeng HC; Wei XL; Zhang GJ
    Front Oncol; 2021; 11():628814. PubMed ID: 34249678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
    Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
    Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease.
    Eriksson ET; Schimmelpenning H; Aspenblad U; Zetterberg A; Auer GU
    Hum Pathol; 1994 Nov; 25(11):1228-33. PubMed ID: 7959668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
    Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
    J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.
    Kulić A; Sirotković-Skerlev M; Jelisavac-Cosić S; Herceg D; Kovac Z; Vrbanec D
    Med Oncol; 2010 Sep; 27(3):887-93. PubMed ID: 19763913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
    Regidor PA; Regidor M; Callies R; Schindler AE
    Eur J Gynaecol Oncol; 1996; 17(3):192-9. PubMed ID: 8780917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
    Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
    Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of serum p53 antibodies in lung cancer.
    Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
    BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer.
    Liu J; Lin Y; Yang H; Deng Q; Chen G; He J
    Tumour Biol; 2011 Dec; 32(6):1113-21. PubMed ID: 21779982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.
    Ellis PA; Lonning PE; Borresen-Dale A; Aas T; Geisler S; Akslen LA; Salter I; Smith IE; Dowsett M
    Br J Cancer; 1997; 76(4):480-5. PubMed ID: 9275025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.